|
1
|
Shirasaka T, Shimamoto Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kawahara M, Furuse K, Segawa Y, Yoshimori
K, Matsui K, Kudoh S, Hasegawa K and Niitani H: S-1 Cooperative
Study Group (Lung Cancer Working Group): Phase II study of S-1, a
novel oral fluorouracil, in advanced non-small-cell lung cancer. Br
J Cancer. 85:939–943. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shiroyama T, Kijima T, Komuta K, Yamamoto
S, Minami S, Ogata Y, Okafuji K, Imamura F, Hirashima T, Tachibana
I, et al: Phase II tailored S-1 regimen study of first-line
chemotherapy in elderly patients with advanced and recurrent
non-small cell lung cancer. Cancer Chemother Pharmacol. 70:783–789.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okamoto I, Yoshioka H, Morita S, Ando M,
Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, et al:
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel
plus carboplatin in chemotherapy-naive patients with advanced
non-small-cell lung cancer: Results of a west Japan oncology group
study. J Clin Oncol. 28:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ono A, Naito T, Murakami H, Takahashi T,
Nakamura Y, Tsuya A, Kaira K, Igawa S, Shukuya T, Tamiya A, et al:
Evaluation of S-1 as third or further-line chemotherapy in advanced
non-small-cell lung cancer. Int J Clin Oncol. 15:161–165. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohyanagi F, Yamamoto N, Horiike A, Harada
H, Kozuka T, Murakami H, Gomi K, Takahashi T, Morota M, Nishimura
T, et al: Phase II trial of S-1 and cisplatin with concurrent
radiotherapy for locally advanced non-small-cell lung cancer. Br J
Cancer. 101:225–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Richardson GE, Thursfield VJ and Giles GG:
Reported management of lung cancer in Victoria in 1993: Comparison
with best practice. Anti-cancer council of victoria lung cancer
study group. Med J Aust. 172:321–324. 2000.PubMed/NCBI
|
|
8
|
Sambrook RJ and Girling DJ: A national
survey of the chemotherapy regimens used to treat small cell lung
cancer (SCLC) in the United Kingdom. Br J Cancer. 84:1447–1452.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gregor A, Thomson CS, Brewster DH, Stroner
PL, Davidson J, Fergusson RJ and Milroy R: Scottish Cancer Trials
Lung Group; Scottish Cancer Therapy Network: Management and
survival of patients with lung cancer in Scotland diagnosed in
1995: Results of a national population based study. Thorax.
56:212–217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lebitasy MP, Hédelin G, Purohit A, Moreau
L, Klinzig F and Quoix E: Progress in the management and outcome of
small-cell lung cancer in a French region from 1981 to 1994. Br J
Cancer. 85:808–815. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang GC, Chen KC, Yang TY, Yin MC, Lin
CP, Kuo BI and Hsu JY: Activity of gefitinib in advanced
non-small-cell lung cancer with very poor performance status.
Invest New Drugs. 23:73–77. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hayashibara K, Satoh H, Shinohara Y,
Inagaki M, Kaburagi T, Hashimoto T, Kurishima K, Ishikawa H,
Ichimura H, Nawa T, et al: A population-based study of gefitinib in
patients with non-small cell lung cancer. Med Oncol. 26:222–227.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakamura H, Satoh H, Kaburagi T, Nishimura
Y, Shinohara Y, Inagaki M, Endo T, Saito T, Hayashihara K, Hizawa
N, et al: Bevacizumab-containing chemotherapy for non-small cell
lung cancer patients: A population-based observational study by the
Ibaraki thoracic integrative (POSITIVE) research group. Med Oncol.
29:3202–3206. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaburagi T, Satoh H, Hayashihara K, Endo
T, Hizawa N, Kurishima K, Nishimura Y, Hashimoto T, Nakamura H,
Kishi K, et al: Observational study on the efficacy and safety of
erlotinib in patients with non-small cell lung cancer. Oncol Lett.
5:435–439. 2013.PubMed/NCBI
|
|
15
|
Cancer Therapy Evaluation Program, Common
Toxicity Criteria for Adverse Events. Version 3.0, CTCAE Version
3.0. June 10–2003.http://ctep.cancer.govAccessed. May 15–2014
|
|
16
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen YM: Update of epidermal growth factor
receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
J Chin Med Assoc. 76:249–257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Totani Y, Saito Y, Hayashi M, Tada T,
Kohashi Y, Mieno Y, Kato A, Imizu H, Yoneda Y, Hoshino T, et al: A
phase II study of S-1 monotherapy as second-line treatment for
advanced non-small cell lung cancer. Cancer Chemother Pharmacol.
64:1181–1185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Katakami N, Gemma A, Sakai H, Kubota K,
Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, et
al: Randomized phase III trial of S-1 plus cisplatin versus
docetaxel plus cisplatin for advanced non-small-cell lung cancer
(TCOG0701). J Clin Oncol. 30(Suppl): abstract 75152012.
|
|
20
|
Yoshioka H, Okamoto I, Morita S, Ando M,
Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, et al:
Efficacy and safety analysis according to histology for S-1 in
combination with carboplatin as first-line chemotherapy in patients
with advanced non-small-cell lung cancer: Updated results of the
West Japan Oncology Group LETS study. Ann Oncol. 24:1326–1331.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ichinose Y, Seto T, Sasaki T, Yamanaka T,
Okamoto I, Takeda K, Tanaka M, Katakami N, Sawa T, Kudoh S, et al:
S-1 plus cisplatin with concurrent radiotherapy for locally
advanced non-small cell lung cancer: A multi-institutional phase II
trial (West Japan Thoracic Oncology Group 3706). J Thoracic Oncol.
6:2069–2075. 2011. View Article : Google Scholar
|
